In this analysis, AD patients were stratified according to CSF t-tau levels into high CSF t-tau levels and low CSF t-tau levels, using as cut-off value the median of CSF tau levels of our entire sample (680 pg/ml). The gene discussed is MAPT; the disease is Alzheimer disease.